The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...
Investor's Business Daily on MSN
IBD stock of the day, LivaNova, forms a unique base; will new opportunities drive it higher?
LivaNova is Wednesday's IBD Stock Of The Day. After a trio of pullbacks, the medical devices stock is making a run at a flat ...
Boston Scientific (NYSE:BSX) has completed the acquisition of Nalu Medical, expanding its presence in chronic pain treatment. The company has announced a pending US$14.5b deal for Penumbra, which ...
Medical Device Network on MSN
Abbott touts neuromodulation portfolio’s long-term benefits
Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...
The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...
ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...
Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, ...
Resonetics said buying Resolution Medical would expand its capabilities in neuromodulation, structural heart and ...
Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results